β-Blockers in dialysis patients: a nephrocardiology perspective.
作者信息
Shroff Gautam R, Herzog Charles A
机构信息
Division of Cardiology, Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota, and.
Division of Cardiology, Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota, and Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota
出版信息
J Am Soc Nephrol. 2015 Apr;26(4):774-6. doi: 10.1681/ASN.2014080831. Epub 2014 Oct 30.
Abstract
摘要
相似文献
1
β-Blockers in dialysis patients: a nephrocardiology perspective.透析患者中的β受体阻滞剂：肾脏心脏病学视角
J Am Soc Nephrol. 2015 Apr;26(4):774-6. doi: 10.1681/ASN.2014080831. Epub 2014 Oct 30.
2
Beta-blockade in chronic dialysis patients.慢性透析患者的β受体阻滞剂治疗
Semin Dial. 2008 Jan-Feb;21(1):43-8. doi: 10.1111/j.1525-139X.2007.00367.x.
3
Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.β受体阻滞剂在透析患者中的心血管结局：加拿大安大略省的队列研究。
Nephrol Dial Transplant. 2012 Apr;27(4):1591-8. doi: 10.1093/ndt/gfr460. Epub 2011 Aug 26.
4
The intuitive case for β-blockers in patients with ESRD.终末期肾病（ESRD）患者使用β受体阻滞剂的直观依据。
Semin Dial. 2012 Jan-Feb;25(1):15-21. doi: 10.1111/j.1525-139X.2011.01016.x.
5
[General anesthesia in the hypertensive dialyzed renal failure patient treated with beta-blockers].[接受β受体阻滞剂治疗的高血压透析肾衰竭患者的全身麻醉]
Nouv Presse Med. 1979 Oct 15;8(39):3167.
6
The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study.β受体阻滞剂降低心血管透析事件（BLOCADE）可行性研究的基本原理与设计
Nephrology (Carlton). 2015 Mar;20(3):140-7. doi: 10.1111/nep.12362.
7
Beta blockers in patients with end-stage renal disease-Evidence-based recommendations.终末期肾病患者使用β受体阻滞剂——循证推荐
Semin Dial. 2018 May;31(3):219-225. doi: 10.1111/sdi.12691. Epub 2018 Feb 26.
8
[Dialysis-associated hypertension].[透析相关性高血压]
Nihon Rinsho. 1992 Jan;50 Suppl:663-8.
9
[Treatment by beta-blockers of arterial hypertension in patients with chronic renal insufficiency on hemodialysis].[β受体阻滞剂对接受血液透析的慢性肾功能不全患者动脉高血压的治疗]
Nouv Presse Med. 1978 Sep 20;7(31):2799-801.
10
Special considerations for antihypertensive agents in dialysis patients.透析患者的降压药物的特殊考虑因素。
Blood Purif. 2010;29(2):93-8. doi: 10.1159/000245631. Epub 2010 Jan 8.
引用本文的文献
1
Sodium First Approach, to Reset Our Mind for Improving Management of Sodium, Water, Volume and Pressure in Hemodialysis Patients, and to Reduce Cardiovascular Burden and Improve Outcomes.钠优先策略，旨在重置我们的思维，以改善血液透析患者钠、水、容量和血压的管理，减轻心血管负担并改善预后。
Front Nephrol. 2022 Jul 7;2:935388. doi: 10.3389/fneph.2022.935388. eCollection 2022.
2
Antihypertensive Medications Use among Chronic Hemodialysis Patients Visiting the Outpatient Department of Nephrology of a Tertiary Care Centre: A Descriptive Cross-sectional Study.在一家三级保健中心的肾病科门诊就诊的慢性血液透析患者中使用抗高血压药物：一项描述性横断面研究。
JNMA J Nepal Med Assoc. 2023 Mar 1;61(259):255-258. doi: 10.31729/jnma.8095.
3
Association Between Lipophilic Beta-Blockers and Depression in Diabetic Patients on Chronic Dialysis.慢性透析糖尿病患者中亲脂性β受体阻滞剂与抑郁症之间的关联
Clin Med Insights Endocrinol Diabetes. 2022 Aug 29;15:11795514221119446. doi: 10.1177/11795514221119446. eCollection 2022.
4
Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis.比索洛尔与卡维地洛在维持性血液透析患者中的疗效比较。
Clin Kidney J. 2021 Jan 4;14(3):983-990. doi: 10.1093/ckj/sfaa248. eCollection 2021 Mar.
5
Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.维持性透析患者降压药物治疗的疗效和安全性比较：一项随机对照试验的网络荟萃分析。
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1129-1138. doi: 10.2215/CJN.12201019. Epub 2020 Jul 16.
6
Timing of blood pressure medications and intradialytic hypotension.血压药物的服用时间与透析中低血压
Semin Dial. 2019 May;32(3):201-204. doi: 10.1111/sdi.12777. Epub 2019 Mar 5.
本文引用的文献
1
β-Blocker dialyzability and mortality in older patients receiving hemodialysis.接受血液透析的老年患者中β受体阻滞剂的透析性与死亡率
J Am Soc Nephrol. 2015 Apr;26(4):987-96. doi: 10.1681/ASN.2014040324. Epub 2014 Oct 30.
2
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.阿替洛尔或赖诺普利治疗血液透析患者高血压的随机对照试验。
Nephrol Dial Transplant. 2014 Mar;29(3):672-81. doi: 10.1093/ndt/gft515. Epub 2014 Jan 6.
3
Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.探索透析中高血压的机制：以血管内皮细胞功能障碍为靶点的初步研究。
Clin J Am Soc Nephrol. 2012 Aug;7(8):1300-9. doi: 10.2215/CJN.10010911. Epub 2012 Jun 14.
4
The intuitive case for β-blockers in patients with ESRD.终末期肾病（ESRD）患者使用β受体阻滞剂的直观依据。
Semin Dial. 2012 Jan-Feb;25(1):15-21. doi: 10.1111/j.1525-139X.2011.01016.x.
5
Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.医疗保险部分 D 中透析患者心血管疾病药物的使用和费用。
Am J Kidney Dis. 2012 May;59(5):670-81. doi: 10.1053/j.ajkd.2011.10.047. Epub 2011 Dec 28.
6
β-blocker prevents sudden cardiac death in patients with hemodialysis.β 受体阻滞剂可预防血液透析患者心源性猝死。
Int J Cardiol. 2013 May 25;165(3):519-22. doi: 10.1016/j.ijcard.2011.09.037. Epub 2011 Oct 11.
7
Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.β受体阻滞剂在透析患者中的心血管结局：加拿大安大略省的队列研究。
Nephrol Dial Transplant. 2012 Apr;27(4):1591-8. doi: 10.1093/ndt/gfr460. Epub 2011 Aug 26.
8
β-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study.β 受体阻滞剂预防血液透析患者心源性猝死：HEMO 研究的倾向评分分析。
Am J Kidney Dis. 2011 Dec;58(6):939-45. doi: 10.1053/j.ajkd.2011.06.024. Epub 2011 Aug 27.
9
HFSA 2010 Comprehensive Heart Failure Practice Guideline.HFSA 2010 全面心力衰竭治疗指南。
J Card Fail. 2010 Jun;16(6):e1-194. doi: 10.1016/j.cardfail.2010.04.004.
10
Beta-blockade in chronic dialysis patients.慢性透析患者的β受体阻滞剂治疗
Semin Dial. 2008 Jan-Feb;21(1):43-8. doi: 10.1111/j.1525-139X.2007.00367.x.
Zotero 插件